Caroline Schmitz WIlliams
Caroline is the founder and executive director of The Fenbendazole Foundation, a nonprofit organization dedicated to expanding public access to knowledge, research, and community support around the potential health benefits of fenbendazole. Having emerged as a key thought leader, visionary, advocate, and leader of the Fenbendazole movement, Caroline also became a successful entrepreneur, now managing a portfolio of multimillion-dollar wellness brands that she built from the ground up.
Still, her focus remains on service in all her ventures. She doesn’t pretend to have all the answers like some guru or influencer. Caroline’s story, like the community she serves, is deeply human. Caroline is the first to say she’s a normal person with real struggles, someone who learns and grows the hard way: through experience, mistakes, and perseverance. Caroline’s Christian faith is at the heart of everything she does. She believes deeply in Jesus, and it is that faith that motivates her to serve the disease community with humility, compassion, and hope. For her, giving back isn’t about prestige—it’s about purpose. It’s about showing others that there is life, and healing, beyond the chaos.
A proud Midwesterner and loving mother of two boys, Caroline’s interest in alternatives to standard medical care began years ago when her family received a Jenny McCarthy Rescue Family Grant. That experience opened the door to unexpected breakthroughs, including finding relief for her children’s autism symptoms through antifungal therapies outside the boundaries of conventional protocols. It was a moment that would change the course of her life.
Years later, when Caroline faced her own health crisis, she encountered the same frustrating maze that many patients know all too well: a medical rat race of disconnected specialists, unclear answers, and the painful gaps in a system where no one doctor could provide a comprehensive view. “Nothing made sense,” she says, “so I decided to take control.” That decision marked the beginning of her path as a researcher, advocate, and builder of hope.
In 2017, Caroline became one of the first public advocates for the potential of human usage of fenbendazole, registering the Fenben® trademark and launching product innovations like Fenben Bio Nasal Spray, starting steps in her mission to make Fenbendazole accessible. Her advocacy work quickly grew into a large-scale social community platform for Fenbendazole discussion and education followed by her founding of Happy Healing, Inc. before she founded the Fenbendazole Foundation in 2022.
Today, through the Foundation, its resource hub FenbendazoleHelp.org and the “MyFenben” social media community, Caroline leads a mission grounded in three pillars: research, education, and community. She champions patient access to evidence-informed alternatives, supports scientific inquiry into repurposed compounds, and uplifts voices that are often unheard in traditional healthcare narratives.
Todd Williams
Todd is founding board member of The Fenbendazole Foundation and serves as the organization’s lead advisor on financial management, tax compliance, and long-term sustainability. A veteran with over two decades of experience in corporate finance, operations, and entrepreneurial ventures, Todd plays a critical role in ensuring that the Foundation’s resources are managed responsibly and transparently in alignment with its nonprofit mission.
Throughout his career, Todd has held leadership roles spanning healthcare, real estate, and consumer services. His professional background includes financial operations, risk management, and business development—with a strong focus on strategic growth and regulatory adherence. At the Foundation, he provides governance and oversight for budgeting, reporting, and IRS compliance, helping to ensure that all donations and program investments are aligned with 501(c)(3) standards and best practices.
As one of the organization’s earliest supporters, Todd helped lay the groundwork for The Fenbendazole Foundation’s launch, including guiding its corporate structure, filing for nonprofit status, and developing scalable financial systems. His pragmatic, integrity-driven approach helps ensure that the Foundation remains both mission-aligned and operationally sound.
Aaron Joseph Henry Pendola
Aaron brings a dynamic background in biomedical information technology (IT), public health, pharmaceutical/nutraceutical/biologics R&D and regulatory compliance to his role on the Board of Directors at the Fenbendazole Foundation. With more than a decade of experience across federal research and regulatory agencies and biomedical mission-driven private ventures, Aaron is committed to advancing credible, community-centered research on fenbendazole and its potential applications in cancer and infectious disease into a government-regulated and a popularly-accepted movement amongst the medical mainstream.
Aaron’s journey in drug discovery began by providing technical, scientific, and professional support services to the US Department of Health and Human Services (HHS), where he supported major government research initiatives focused on pharmaceutical and biologics product R&D in the fields of oncology, virology, and translational science. As a government contract business developer, grant writer, and program manager, Aaron has helped manage, shape, and fund some of the country’s most ambitious biomedical research portfolios including at the National Institutes of Health (NIH), National Institutes of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), US Food and Drug Administration (FDA), and other government organizations.
In the private sector, Aaron has also been a pioneer in the regulated medical cannabis industry. As partner at Missouri’s award-winning medical marijuana consulting practice A2C, state cannabis licensee, and key personnel supporting Missouri’s state constitutional amendment cannabis elections - Aaron provided comprehensive support across the lifecycle of drug legalization, implementation, and regulation. He merged US Federal-based scientific program management methodologies with the existing market for cannabis—developing compliance pathways and regulated business frameworks for cannabinoids in clinical use. His unique combination of government acumen, policy and regulatory insight, and entrepreneurial drive positions him to illuminate fenbendazole's emerging role in complementary cancer and infectious disease research via his collaborative approach to engaging government stakeholders for the benefit the Fenbendazole community.
At Fenbendazole Foundation, Aaron is focused on building infrastructure for responsible scientific inquiry, grant readiness, and collaborative partnerships with academic, clinical, and public health stakeholders. Having participated in Caroline’s fenbendazole social media community for over 7 years, Aaron is passionate about ensuring that Caroline Williams’ vision to promote and celebrate promising compounds like fenbendazole so that they are not overlooked due to lack of institutional ownership or commercial bias.